US20130146050A1 - Nasal spray apparatus - Google Patents
Nasal spray apparatus Download PDFInfo
- Publication number
- US20130146050A1 US20130146050A1 US13/811,578 US201113811578A US2013146050A1 US 20130146050 A1 US20130146050 A1 US 20130146050A1 US 201113811578 A US201113811578 A US 201113811578A US 2013146050 A1 US2013146050 A1 US 2013146050A1
- Authority
- US
- United States
- Prior art keywords
- substance
- container
- snoring
- snoring substance
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/08—Inhaling devices inserted into the nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F5/00—Orthopaedic methods or devices for non-surgical treatment of bones or joints; Nursing devices; Anti-rape devices
- A61F5/56—Devices for preventing snoring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
- A61M11/008—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised by squeezing, e.g. using a flexible bottle or a bulb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
- A61M15/0031—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up by bursting or breaking the package, i.e. without cutting or piercing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
Definitions
- the present disclosure generally relates to administering a substance to the throat. More particularly, the aspects of the disclosed embodiments relate to administering a substance to the throat via the nose using a blow-fill-mold style bottle.
- Devices are available for administering active substances or substances to the body, particularly through the throat, lungs or sinuses. These devices generally include containers that have a main chamber holding the desired contents and a head portion that is inserted into the nose or mouth. By squeezing the container, the substance is released into the nose or mouth. In some cases, the device has a tab or seal that must be broken in order to release the substance.
- a relatively narrow neck on the device can form the outlet channel from the main chamber into the head portion. This outlet channel can sealed by a frangible membrane that is typically formed by placing a crimp, tab or seal across the head portion during the molding and sealing process.
- the head portion is broken away from the main chamber portion, thus opening the outlet channel and allowing removal or dispensing of the contents.
- the user will typically inhale at roughly the same time as the substance is released in order to force the medicine into, or further into, the sinus cavity, throat or lungs.
- blow-fill-seal process also referred to herein as blow-fill-mold
- blow-fill-mold is a single operation which produces sterile containers. Bottles or vials made from materials such as from thermoplastic, are blown to a desired shape and immediately on cooling are filled aseptically with a desired fluid and hermetically sealed.
- the containers that are produced by the blow-fill-seal process are generally referred to herein as “BFS containers.”
- the blow-fill seal process generally produces compact, easy-to-use substance dispensing devices that can be used to deliver substance to the throat, lungs or sinuses.
- Snoring is a serious problem for a large segment of the population.
- Snoring is a sleep disorder that can range from mild to severe in humans. Mild cases may result in no more than fitful sleep by the sufferer, while severe cases can cause disturbance of the sleep of others, and may result in insufficient inhalation of oxygen by the sufferer, apnea and, in extreme cases, death.
- Remedies to alleviate the symptoms of snoring can range from surgery to a variety of substances. Although surgery has been proven to be somewhat effective, it is a radical and expensive approach that is subject to all the usual risks associated with surgery. Drugs are available by prescription for the treatment of the symptoms of snoring. Other snoring management techniques can include for example, mechanical aids, nasal strips and anti-snoring sprays. Anti-snoring sprays can tend to be ineffective unless applied repeatedly during the night. Additionally, device sterilization is a concern when administering anti-snoring sprays due to the potential for infection since the sprays are introduced directly into the lungs in a manner that at least partially bypasses the patient's natural defense mechanisms.
- the exemplary embodiments of the present invention overcome one or more of the above or other disadvantages known in the art.
- the disclosed embodiments are directed to a pharmaceutical product in the form of an anti-snoring substance.
- the product includes a container containing the anti-snoring substance; the anti-snoring substance being in the form of a solution pre-concentrate; the container being made by a blow-fill-seal technology, wherein the container material is Polyethylene or Polypropylene; the container including a body portion containing the anti-snoring substance and a fluid outlet portion configured to deliver the anti-snoring substance.
- the disclosed embodiments are directed to a method for administering an anti-snoring substance.
- the method includes sealing a unit dose of the anti-snoring substance in a container made by a blow-fill-seal technology; opening the unit dose; administering the anti-snoring substance to a nasal passage of a patient while a head of the patient is in a substantially backward tilted position in order for the substance to reach a throat of the patient, wherein the anti-snoring substance is delivered into the nasal passage in the form of a jet stream.
- the disclosed embodiments are directed to a nasal spray apparatus.
- the apparatus includes a nasal preparation containing an anti-snoring substance; a container having an opening that provides access to an interior cavity, which container is operable to hold the anti-snoring substance within the interior cavity; a pump dispenser mounted on the container in a manner that closes the opening; wherein the container and pump dispenser are manufactured by a blow-fill-mold process.
- FIG. 1 illustrates an exemplary dispensing device incorporating aspects of the present disclosure.
- FIG. 2 illustrates a use application of the dispensing device incorporating aspects of the disclosed embodiments.
- FIG. 1 a device 102 for the nasal or oral delivery of a substance is shown.
- the aspects of the disclosed embodiments are generally directed to the administration of an anti-snoring substance or medicament to a patient with a device manufactured using blow-fill-seal or blow-fill-mold technology.
- the device 102 shown in FIG. 1 is part of an ampule pack 100 .
- the device 102 comprises a sealed flexible container or body portion 104 containing the substance or medicament.
- the device 102 is typically manufactured using a blow-fill-seal or blow-fill-mold technique.
- the device 102 generally comprises a body portion 104 and a fluid outlet portion 106 .
- the body portion 104 is configured to hold the nasal preparation, also referred to herein as the anti-snoring substance.
- the device 102 includes a tab portion 108 , which is generally configured to be of a twist off type.
- a frangible member 110 can be included on the fluid outlet portion 106 near or as part of the tab portion 108 , to allow the tab portion 108 to be easily removed.
- the device 102 is substantially filled with the anti-snoring substance when oriented in the vertical plane and sealed.
- the substance can be dispensed, such as shown in FIG. 2 .
- the substance is generally dispensed by allowing the substance to exit from the fluid outlet portion 106 as the device 102 is positioned with the fluid outlet portion 106 oriented in a substantially downward direction.
- the body portion 104 can be compressed to force or urge the substance from the body portion 104 and out of the fluid outlet portion 106 in the form of a jet stream, rather than a spray or atomization.
- the substance comprises an anti-snoring solution named ASONOR® and manufactured by TannerMedico NS, Denmark.
- the solution contains Sodium Chloride, Glycerol, Polysorbate and Edetatesodium. Potassium sorbate can be added as preservative.
- the solution is filled into the body portion 104 as part of the Blow-Fill-Seal process, as otherwise known in the art.
- the containers 102 are plastic Polypropylene or Polyethylene containers. In alternate embodiments, the containers 102 can comprise any suitable container for use in the Blow-Fill-Seal process. Each container forms a single unit dose.
- FIG. 2 A method of administering the substance according to one aspect of the disclosed embodiments is described with respect to FIG. 2 .
- the head 200 of the user is generally tilted in a backwards or rearwards direction, such as the direction A shown in FIG. 2 , from a substantially upright position, so that the nose 202 is in a substantially horizontal or slightly backward tilted position relative to the ground 204 .
- the head 200 needs to be tilted backwards far enough, for a period of time, to allow the substance to travel through the nasal passages 206 to the throat area 208 .
- gravity will assist in delivering the liquid substance to the throat area 208 through the nasal passages 206 .
- the end 106 of device 100 being used is placed in or near the opening of the nostril 210 .
- the container 220 is then squeezed to deliver the substance into the nasal passage 206 and to the throat passage 208 .
- the container 220 is squeezed a sufficient number of times until the substance is felt in the throat passage 208 or the entire substance is expended.
- the process is repeated for each of the nasal passages 206 .
- three to four pumps into each nostril 210 is sufficient.
- the liquid substance is not intended to remain in the nasal passages 206 , as the benefits of this anti-snoring substance are primarily realized from the substance reaching the throat passage 208 .
- the aspects of the disclosed embodiments provide an effective treatment against snoring.
- An anti-snoring substance and in particular ASONOR®, is administered into the nasal passages using a blow-fill mold style bottle.
- a jet-stream style outlet nozzle rather than a spray or atomization, the substance does not stay in the nose, but is rather delivered to the throat. This advantageously allows the substance to begin working sooner.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Mechanical Engineering (AREA)
- Nursing (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
Abstract
A pharmaceutical product in the form of an anti-snoring substance includes a container (220) containing the anti-snoring substance, the anti-snoring substance being in the form of a solution pre-concentrate. The container (220) is made by a blow-fill-seal technology, wherein the container material is Polyethylene or Polypropylene. The container (220) includes a body portion (104) containing the anti-snoring substance and a fluid outlet portion (106) configured to deliver the anti-snoring substance.
Description
- The present disclosure generally relates to administering a substance to the throat. More particularly, the aspects of the disclosed embodiments relate to administering a substance to the throat via the nose using a blow-fill-mold style bottle.
- Devices are available for administering active substances or substances to the body, particularly through the throat, lungs or sinuses. These devices generally include containers that have a main chamber holding the desired contents and a head portion that is inserted into the nose or mouth. By squeezing the container, the substance is released into the nose or mouth. In some cases, the device has a tab or seal that must be broken in order to release the substance. A relatively narrow neck on the device can form the outlet channel from the main chamber into the head portion. This outlet channel can sealed by a frangible membrane that is typically formed by placing a crimp, tab or seal across the head portion during the molding and sealing process. At the time of use, the head portion is broken away from the main chamber portion, thus opening the outlet channel and allowing removal or dispensing of the contents. When the substance is being administered orally, the user will typically inhale at roughly the same time as the substance is released in order to force the medicine into, or further into, the sinus cavity, throat or lungs.
- The blow-fill-seal process (BFS process), also referred to herein as blow-fill-mold, is a single operation which produces sterile containers. Bottles or vials made from materials such as from thermoplastic, are blown to a desired shape and immediately on cooling are filled aseptically with a desired fluid and hermetically sealed. The containers that are produced by the blow-fill-seal process are generally referred to herein as “BFS containers.” The blow-fill seal process generally produces compact, easy-to-use substance dispensing devices that can be used to deliver substance to the throat, lungs or sinuses.
- Snoring is a serious problem for a large segment of the population. Snoring is a sleep disorder that can range from mild to severe in humans. Mild cases may result in no more than fitful sleep by the sufferer, while severe cases can cause disturbance of the sleep of others, and may result in insufficient inhalation of oxygen by the sufferer, apnea and, in extreme cases, death.
- Remedies to alleviate the symptoms of snoring can range from surgery to a variety of substances. Although surgery has been proven to be somewhat effective, it is a radical and expensive approach that is subject to all the usual risks associated with surgery. Drugs are available by prescription for the treatment of the symptoms of snoring. Other snoring management techniques can include for example, mechanical aids, nasal strips and anti-snoring sprays. Anti-snoring sprays can tend to be ineffective unless applied repeatedly during the night. Additionally, device sterilization is a concern when administering anti-snoring sprays due to the potential for infection since the sprays are introduced directly into the lungs in a manner that at least partially bypasses the patient's natural defense mechanisms.
- Accordingly, it would be desirable to provide a system that addresses at least some of the problems identified above.
- As described herein, the exemplary embodiments of the present invention overcome one or more of the above or other disadvantages known in the art.
- In one aspect, the disclosed embodiments are directed to a pharmaceutical product in the form of an anti-snoring substance. In one embodiment, the product includes a container containing the anti-snoring substance; the anti-snoring substance being in the form of a solution pre-concentrate; the container being made by a blow-fill-seal technology, wherein the container material is Polyethylene or Polypropylene; the container including a body portion containing the anti-snoring substance and a fluid outlet portion configured to deliver the anti-snoring substance.
- In another aspect, the disclosed embodiments are directed to a method for administering an anti-snoring substance. In one embodiment, the method includes sealing a unit dose of the anti-snoring substance in a container made by a blow-fill-seal technology; opening the unit dose; administering the anti-snoring substance to a nasal passage of a patient while a head of the patient is in a substantially backward tilted position in order for the substance to reach a throat of the patient, wherein the anti-snoring substance is delivered into the nasal passage in the form of a jet stream.
- In a further aspect, the disclosed embodiments are directed to a nasal spray apparatus. In one embodiment, the apparatus includes a nasal preparation containing an anti-snoring substance; a container having an opening that provides access to an interior cavity, which container is operable to hold the anti-snoring substance within the interior cavity; a pump dispenser mounted on the container in a manner that closes the opening; wherein the container and pump dispenser are manufactured by a blow-fill-mold process.
- These and other aspects and advantages of the disclosed embodiments will become apparent from the following detailed description considered in conjunction with the accompanying drawings. It is to be understood, however, that the drawings are designed solely for purposes of illustration and not as a definition of the limits of the invention, for which reference should be made to the appended claims. Moreover, the drawings are not necessarily drawn to scale and that, unless otherwise indicated, they are merely intended to conceptually illustrate the structures and procedures described herein.
- In the drawings:
-
FIG. 1 illustrates an exemplary dispensing device incorporating aspects of the present disclosure. -
FIG. 2 illustrates a use application of the dispensing device incorporating aspects of the disclosed embodiments. - Referring now to
FIG. 1 , adevice 102 for the nasal or oral delivery of a substance is shown. The aspects of the disclosed embodiments are generally directed to the administration of an anti-snoring substance or medicament to a patient with a device manufactured using blow-fill-seal or blow-fill-mold technology. Thedevice 102 shown inFIG. 1 is part of anampule pack 100. In one embodiment, thedevice 102 comprises a sealed flexible container orbody portion 104 containing the substance or medicament. Thedevice 102 is typically manufactured using a blow-fill-seal or blow-fill-mold technique. - As shown in
FIG. 1 , thedevice 102 generally comprises abody portion 104 and afluid outlet portion 106. Thebody portion 104 is configured to hold the nasal preparation, also referred to herein as the anti-snoring substance. In one embodiment, thedevice 102 includes atab portion 108, which is generally configured to be of a twist off type. Afrangible member 110 can be included on thefluid outlet portion 106 near or as part of thetab portion 108, to allow thetab portion 108 to be easily removed. - During the blow-fill-seal process, the
device 102 is substantially filled with the anti-snoring substance when oriented in the vertical plane and sealed. When thetab 108 is removed, the substance can be dispensed, such as shown inFIG. 2 . In this embodiment, the substance is generally dispensed by allowing the substance to exit from thefluid outlet portion 106 as thedevice 102 is positioned with thefluid outlet portion 106 oriented in a substantially downward direction. In this example, thebody portion 104 can be compressed to force or urge the substance from thebody portion 104 and out of thefluid outlet portion 106 in the form of a jet stream, rather than a spray or atomization. - In one embodiment, the substance comprises an anti-snoring solution named ASONOR® and manufactured by TannerMedico NS, Denmark. The solution contains Sodium Chloride, Glycerol, Polysorbate and Edetatesodium. Potassium sorbate can be added as preservative. During the manufacturing process, the solution is filled into the
body portion 104 as part of the Blow-Fill-Seal process, as otherwise known in the art. In one embodiment, thecontainers 102 are plastic Polypropylene or Polyethylene containers. In alternate embodiments, thecontainers 102 can comprise any suitable container for use in the Blow-Fill-Seal process. Each container forms a single unit dose. - A method of administering the substance according to one aspect of the disclosed embodiments is described with respect to
FIG. 2 . As shown inFIG. 2 , thehead 200 of the user is generally tilted in a backwards or rearwards direction, such as the direction A shown inFIG. 2 , from a substantially upright position, so that thenose 202 is in a substantially horizontal or slightly backward tilted position relative to the ground 204. Generally, thehead 200 needs to be tilted backwards far enough, for a period of time, to allow the substance to travel through thenasal passages 206 to thethroat area 208. By tilting thehead 200 backwards, gravity will assist in delivering the liquid substance to thethroat area 208 through thenasal passages 206. - Once the
head 200 is in the tilted back position as is shown inFIG. 2 , theend 106 ofdevice 100 being used is placed in or near the opening of thenostril 210. Thecontainer 220 is then squeezed to deliver the substance into thenasal passage 206 and to thethroat passage 208. Thecontainer 220 is squeezed a sufficient number of times until the substance is felt in thethroat passage 208 or the entire substance is expended. The process is repeated for each of thenasal passages 206. Generally, three to four pumps into eachnostril 210 is sufficient. - The liquid substance is not intended to remain in the
nasal passages 206, as the benefits of this anti-snoring substance are primarily realized from the substance reaching thethroat passage 208. - The aspects of the disclosed embodiments provide an effective treatment against snoring. An anti-snoring substance, and in particular ASONOR®, is administered into the nasal passages using a blow-fill mold style bottle. By incorporating a jet-stream style outlet nozzle, rather than a spray or atomization, the substance does not stay in the nose, but is rather delivered to the throat. This advantageously allows the substance to begin working sooner.
- Moreover, it is expressly intended that all combinations of those elements and/or method steps which perform substantially the same function in substantially the same way to achieve the same results are within the scope of the invention. Moreover, it should be recognized that structures and/or elements and/or method steps shown and/or described in connection with any disclosed form or embodiment of the invention may be incorporated in any other disclosed or described or suggested form or embodiment as a general matter of design choice. It is the intention, therefore, to be limited only as indicated by the scope of the claims appended hereto.
Claims (13)
1. A pharmaceutical product comprising:
an anti-snoring substance, the anti-snoring substance comprising a solution pre-concentrate; and
a container containing the anti-snoring substance; the container being made by a blow-fill-seal technology, the container material comprising polyethylene or polypropylene, the container including a body portion containing the anti-snoring substance and a fluid outlet portion configured to deliver the anti-snoring substance.
2. The product according to claim 1 wherein the fluid outlet portion comprises a jet stream nozzle.
3. The product according to claim 1 wherein the container is a squeeze device.
4. The product according to claim 1 wherein the anti-snoring substance is administered through a patient's nasal passage.
5. The product according to claim 4 wherein the anti-snoring substance is administered through the nasal passage to a the patient's throat.
6. The product according to claim 1 wherein the container includes a unit dose of the anti-snoring substance.
7. The product according to claim 6 , wherein the unit dose is delivered in multiple delivery increments.
8. A method of administering an anti-snoring substance comprising: sealing a unit dose of the anti-snoring substance in a container made by a blow-fill-seal technology; opening the unit dose; administering the anti-snoring substance to a nasal passage of a patient while a head of the patient is in a substantially backward tilted position in order for the substance to reach the patient's throat, wherein the anti-snoring substance is delivered into the nasal passage in the form of a jet stream.
9. The method of claim 8 wherein the anti-snoring substance is administered by squeezing the container.
10. A nasal spray apparatus comprising: a nasal preparation containing an anti-snoring substance; a container having an opening that provides access to an interior cavity, the container being configured to hold the anti-snoring substance within the interior cavity; and the container being manufactured by a blow-fill-mold process.
11. The apparatus of claim 10 wherein the container further comprises a nozzle and nozzle tip, and wherein the nozzle tip delivers the anti-snoring substance in the form of a jet stream.
12. The apparatus of claim 10 wherein the substance is delivered by a jet stream through a nasal passage into a patient's throat passage.
13. The apparatus of claim 10 wherein the apparatus includes a single dose of the anti-snoring substance and is disposable.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/811,578 US20130146050A1 (en) | 2010-07-23 | 2011-05-30 | Nasal spray apparatus |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/842,267 US9132243B2 (en) | 2010-07-23 | 2010-07-23 | Method of administering a substance to the throat |
US12/842267 | 2010-07-23 | ||
US13/811,578 US20130146050A1 (en) | 2010-07-23 | 2011-05-30 | Nasal spray apparatus |
PCT/EP2011/058844 WO2012010358A1 (en) | 2010-07-23 | 2011-05-30 | Nasal spray apparatus |
Publications (1)
Publication Number | Publication Date |
---|---|
US20130146050A1 true US20130146050A1 (en) | 2013-06-13 |
Family
ID=44119339
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/842,267 Active US9132243B2 (en) | 2010-07-23 | 2010-07-23 | Method of administering a substance to the throat |
US13/811,578 Abandoned US20130146050A1 (en) | 2010-07-23 | 2011-05-30 | Nasal spray apparatus |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/842,267 Active US9132243B2 (en) | 2010-07-23 | 2010-07-23 | Method of administering a substance to the throat |
Country Status (8)
Country | Link |
---|---|
US (2) | US9132243B2 (en) |
EP (1) | EP2595685B1 (en) |
CN (2) | CN105709316A (en) |
DK (1) | DK2595685T3 (en) |
ES (1) | ES2552506T3 (en) |
HU (1) | HUE025975T2 (en) |
PL (1) | PL2595685T3 (en) |
WO (1) | WO2012010358A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019036483A1 (en) * | 2017-08-15 | 2019-02-21 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK201400720A1 (en) * | 2014-12-11 | 2015-08-24 | Tannermedico As | Anti-Snoring Composition |
AU2016207010A1 (en) | 2015-01-12 | 2017-08-03 | Kedalion Therapeutics, Inc. | Micro-droplet delivery device and methods |
WO2016164830A1 (en) | 2015-04-10 | 2016-10-13 | Lagunita Llc | Piezoelectric dispenser with replaceable ampoule |
EP3338803A1 (en) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmaceutical dosage forms containing inhibitors for task-1 and task-3 channels and their use in therapy of respiratory disorders |
EP3338764A1 (en) | 2016-12-21 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Pharmaceutical dosage forms containing inhibitors for task-1 and task-3 channels and their use in therapy of respiratory disorders |
JOP20190148A1 (en) | 2016-12-21 | 2019-06-18 | Bayer Pharma AG | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy |
JOP20190141A1 (en) | 2016-12-21 | 2019-06-12 | Bayer Pharma AG | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy |
KR102550534B1 (en) | 2017-01-20 | 2023-07-03 | 노파르티스 아게 | Piezoelectric fluid dispenser |
JP7436363B2 (en) | 2017-12-08 | 2024-02-21 | ノバルティス アーゲー | fluid delivery alignment system |
US11039982B1 (en) * | 2017-12-14 | 2021-06-22 | Suzanne L. Spurr, Pharm.D. LLC | Medication delivery device |
JOP20210121A1 (en) | 2018-11-27 | 2023-01-30 | Bayer Ag | Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy |
US11679028B2 (en) | 2019-03-06 | 2023-06-20 | Novartis Ag | Multi-dose ocular fluid delivery system |
US11938057B2 (en) | 2020-04-17 | 2024-03-26 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
EP4120974A4 (en) | 2020-04-17 | 2024-05-22 | Bausch Lomb Ireland Ltd | Hydrodynamically actuated preservative free dispensing system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090071108A1 (en) * | 2007-09-14 | 2009-03-19 | Mystic Pharmaceuticals, Inc. | Deep draw container forming method |
US20100193380A1 (en) * | 2007-05-16 | 2010-08-05 | Mystic Pharmaceuticals, Inc. | Combination unit dose dispensing containers |
US8771711B2 (en) * | 2006-04-21 | 2014-07-08 | Toko Yakuhin Kogyo Kabushiki Kaisha | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1450744A (en) * | 1919-07-31 | 1923-04-03 | Kelley Thomas Franklin | Plate holding and guiding apparatus |
FR1240547A (en) * | 1959-07-25 | 1960-09-09 | Ampoule in particular for the introduction of remedies into the nose or similar applications | |
US3782066A (en) | 1971-04-26 | 1974-01-01 | Ind Werke Karlsruke Augsburg A | Method of making and filling an aseptic packing container |
US4150744A (en) * | 1976-02-27 | 1979-04-24 | Smith & Nephew Pharmaceuticals Ltd. | Packaging |
WO1998025829A1 (en) * | 1996-12-09 | 1998-06-18 | Bausch & Lomb Incorporated | Single-use flexible container |
US6383166B1 (en) | 1997-03-14 | 2002-05-07 | Zephyr Cove | Plungerless syringe: method and apparatus |
US6062213A (en) | 1998-06-16 | 2000-05-16 | Fuisz Technologies Ltd. | Single unit dose inhalation therapy device |
GB0114272D0 (en) * | 2001-06-12 | 2001-08-01 | Optinose As | Nasal delivery device |
US7100600B2 (en) * | 2001-03-20 | 2006-09-05 | Aerogen, Inc. | Fluid filled ampoules and methods for their use in aerosolizers |
GB2380410B (en) | 2001-10-05 | 2003-11-19 | Alchemy Healthcare Ltd | Apparatus for the nasal or oral delivery of a medicament |
CA2485530A1 (en) | 2002-02-15 | 2003-08-28 | Cns, Inc. | Throat spray |
US7404489B1 (en) * | 2003-03-04 | 2008-07-29 | Qol Medical, Llc | Cyanocobalamin low viscosity aqueous formulations for intranasal delivery |
US8016162B2 (en) * | 2006-06-30 | 2011-09-13 | H.J. Heinz Company | Condiment bottle |
CN201006155Y (en) * | 2007-02-12 | 2008-01-16 | 李竹岩 | Nasal cavity sealed soup injector |
ES2493641T3 (en) * | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Nasal administration of aqueous corticosteroid solutions |
MX2010003935A (en) * | 2007-10-12 | 2010-09-24 | Map Pharmaceuticals Inc | Inhalation drug delivery. |
DE102007056462B4 (en) * | 2007-11-23 | 2011-10-27 | Pari Pharma Gmbh | Disposable ampoule for a device for generating aerosols |
-
2010
- 2010-07-23 US US12/842,267 patent/US9132243B2/en active Active
-
2011
- 2011-05-30 ES ES11722435.2T patent/ES2552506T3/en active Active
- 2011-05-30 DK DK11722435.2T patent/DK2595685T3/en active
- 2011-05-30 HU HUE11722435A patent/HUE025975T2/en unknown
- 2011-05-30 US US13/811,578 patent/US20130146050A1/en not_active Abandoned
- 2011-05-30 EP EP11722435.2A patent/EP2595685B1/en active Active
- 2011-05-30 PL PL11722435T patent/PL2595685T3/en unknown
- 2011-05-30 CN CN201610092228.7A patent/CN105709316A/en active Pending
- 2011-05-30 WO PCT/EP2011/058844 patent/WO2012010358A1/en active Application Filing
- 2011-05-30 CN CN2011800361790A patent/CN103052419A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8771711B2 (en) * | 2006-04-21 | 2014-07-08 | Toko Yakuhin Kogyo Kabushiki Kaisha | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation |
US20100193380A1 (en) * | 2007-05-16 | 2010-08-05 | Mystic Pharmaceuticals, Inc. | Combination unit dose dispensing containers |
US20090071108A1 (en) * | 2007-09-14 | 2009-03-19 | Mystic Pharmaceuticals, Inc. | Deep draw container forming method |
Non-Patent Citations (1)
Title |
---|
TannerMedico Final Report "The Effect of Nasal Application of ASONOR and Polyglyside 80 on Snoring and Sleep Apnea" Dated 20 November 1989 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019036483A1 (en) * | 2017-08-15 | 2019-02-21 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
US11344562B2 (en) * | 2017-08-15 | 2022-05-31 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
Also Published As
Publication number | Publication date |
---|---|
CN105709316A (en) | 2016-06-29 |
HUE025975T2 (en) | 2016-05-30 |
US9132243B2 (en) | 2015-09-15 |
DK2595685T3 (en) | 2016-01-25 |
WO2012010358A1 (en) | 2012-01-26 |
ES2552506T3 (en) | 2015-11-30 |
EP2595685B1 (en) | 2015-10-21 |
US20120017898A1 (en) | 2012-01-26 |
EP2595685A1 (en) | 2013-05-29 |
CN103052419A (en) | 2013-04-17 |
PL2595685T3 (en) | 2016-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9132243B2 (en) | Method of administering a substance to the throat | |
TWI496594B (en) | Gel-type formulation for spray adherable to skin/mucosa and administration system thereof | |
JP4546699B2 (en) | Spray equipment | |
US6666359B2 (en) | Controlled-dose dispenser with integral nozzle and cap | |
JP2005508220A (en) | Medicinal composition preparation tool | |
MXPA06014264A (en) | Dry powder inhaler. | |
US20090182291A1 (en) | Eye medicament dispenser | |
HU211712B (en) | Tool for dosing liquid material | |
WO2011013003A2 (en) | Intranasal granisetron and nasal applicator | |
US11771539B2 (en) | Liquid applicator for delivering vaccines | |
MX2007016521A (en) | Breath actuated drug delivery system. | |
HU217896B (en) | Inhalation device | |
JP2015535450A (en) | Fluid storage device for aerosol generator, combination of fluid storage device and primary fluid packaging, and aerosol generator for use with fluid storage device | |
JP2015535450A5 (en) | ||
JP2020534980A (en) | Intranasal delivery device | |
US20140373831A1 (en) | Pre-filled disposable nebulizer chamber | |
JP2002534331A (en) | Volume and delivery system | |
US20040149774A1 (en) | Liquid disposable plastic container | |
JP5394440B2 (en) | Inhaler | |
WO2015097034A1 (en) | Single dose dry powder inhaler | |
KR20160070105A (en) | Device for delivery of an aerosol substance | |
US20210330584A1 (en) | Topical preparations of drug delivery for nasal and sinus irrigation | |
JPH0454971A (en) | Aerosol drug administration method | |
CN210114722U (en) | Single-dose or small-dose nasal spray device | |
Bommer | Drug delivery: nasal route |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TANNERMEDICO A/S, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ARNFELDT MOLLER, RENE;REEL/FRAME:029887/0081 Effective date: 20130214 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |